Company: CRAC
Filing Date: 2025-10-20
Form Type: POS462C
Source: 0001213900-25-100119
Chunk: 169

Company: Crown Reserve Acquisition Corp. I
Filing Date: 2025-10-20
Form: POS462C
Chunk 169
---
 over 25 years of experience in the pharmaceutical industry, specializing in Active Pharmaceutical Ingredients (API) and finished dosage form distribution. Mr.Doshi has served as a President of Allied Pharma since 2015. Since 2015, Mr.Doshi has driven strategic initiatives and leveraged his extensive expertise to fuel growth and innovation in pharmaceutical and biotech companies like AlfaGene Bioscience, Inc., where he serves as President and CEO. In addition to his roles at Allied Pharma and AlfaGene Bioscience,Inc., Mr.Doshi has served as a director of TRxADE Health, Inc. (NASDAQ: MEDS), now Scienture Holdings Inc. (NASDAQ: SCNX) since May 2024 and is a director of Saptalis Pharmaceuticals. He was also on the board of Powerup Acquisitions Corp. (NASDAQ: PWUP) from August 2023 until its business combination into Aspire BioPharma Inc. (NASDAQ: ASBP) in February 2025. Mr.Doshi is an active investor in emerging fields such as stem cell research, immunology, reverse mergers and SPACs. His contributions 104 extend beyond the corporate realm; he is also involved with Shrimad Rajchandra Mission Dharampur (SRMD), a spiritual organization dedicated to inner development and community service. He received a Master’s in Chemical Engineering from Manhattan College. The past performance of our sponsor, directors, officers, and advisors is not a guarantee either (i) of success with respect to any business combination we may consummate or (ii) that we will be able to identify a suitable candidate for our initial business combination. As described in this prospectus, our advisor, some of our officers and directors have had management experience with blank check companies or special purpose acquisition companies in the past. You should not rely on their respective historical records or performance as indicative of our future performance. Our officers and directors are not prohibited from becoming either a director or officer of any other special purpose acquisition company with a class of securities registered under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Previous SPAC Experience The following is the status of each SPAC that our Directors, Officers, and Director Nominees have served as a Director, Officer or Board Advisor: •Oceantech Acquisitions I Corp. (NASDAQ: OTAC) — Mr. Peterson has served as director since March 2023. Mr. Fell has served as director since March 2023